Panitumumab

<

ASCO 2020: The phase 2 PANDA study in elderly mCRC patients with RAS-BRAF wt tumors showed that 5FU/LV plus panitumumab followed by panitumumab maintenance until PD might be an option.

ESMO 2019: Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer

Results from the randomized VOLFI trial (AIO KRK-0109) showed that the increased toxicity with FOLFOXIRI+/- panitumumab treatment did not translate into impaired quality of life. (Poster 580P, M. Geissler et al.).
A retrospective analysis of PRIME study (FOLFOX +/- Panitumumab as 1L in mCRC) assessed whether Köhne category predicts Early Tumor Shrinkage and Depth of Response and whether survival outcomes of patients achieving ETS or high DpR differ according to baseline Köhne category.
Material90
Panitumumab posters at ESMO

PANITUMUMAB

CONGRESS DATA

ASCO 2019

Final results of the VOLFI trial with Panitumumab plus mFOLFOXIRI in mCRC

Dr. Geissler comments that this four-drug regimen Panitumumab with mFOLFOXIRI may be a valuable treatment option in fit patients with high tumor load.

Conditions d'utilisation:
Les informations médico-scientifiques sur ce site www.science.amgen.ch sont destinées exclusivement au personnel professionnel de la santé en Suisse.

Je ne fais pas partie du personnel professionnel de la santé.